Mesenchymal stem cells for multiple system atrophy

The aim of this trial is to asses the efficacy of autologous mesenchymal stem cell (MSCs) infusions for the treatment of multiple system atrophy. MSCs delayed the progression of neurological deficits with no serious adverse events.